Vertex Pharmaceuticals Inc
Change company Symbol lookup
Select an option...
VRTX Vertex Pharmaceuticals Inc
NOK Nokia Oyj
WPG Washington Prime Group Inc
VIVC Vivic Corp
CBRL Cracker Barrel Old Country Store Inc
BA Boeing Co
MSFT Microsoft Corp
GRPN Groupon Inc
JPM JPMorgan Chase & Co
BIDU Baidu Inc
Go

Health Care : Biotechnology | Large Cap GrowthCompany profile

Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications. The Company's marketed medicines are ORKAMBI and KALYDECO. ORKAMBI (lumacaftor in combination with ivacaftor) is approved as a treatment for patients having two copies (homozygous) of the Delta-F508 (F508del) mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene. KALYDECO (ivacaftor) is approved for the treatment of CF patients having the G551D mutation or other specified mutations in their CFTR gene. The Company's development programs in the field of CF include Tezacaftor (VX-661), VX-152, VX-440, VX-659, VX-445 and VX-371. VX-152, VX-440, VX-659 and VX-445 are CFTR corrector compounds.

Postmarket

Last Trade
Delayed
$168.52
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--

Market Hours

Closing Price
$168.52
Day's Change
0.36 (0.21%)
Bid close
--
Ask close
--
B/A Size
--
Day's High
169.86
Day's Low
166.20
Volume
(Light)
Volume:
1,205,655

10-day average volume:
1,615,489
1,205,655
  • Prev Close
    168.16
  • Today's Open
    167.79
  • Day's Range
    166.20-169.86
  • Avg Vol (10-day)
    1.6M
  • Last (time)
    4:00p ET 04/22/19
  • Last (size)
    13
  • 52-Wk Range
    144.07 - 195.81
    LowHigh
  • (06/06/18 - 01/22/19)
    16.97%
  • 32.2%
  • Market Cap
    43.1B
  • Shares Outstanding
    255.7M
  • 2.07
  • 81.34x
  • No dividend
  • Ex-dividend
    No dividend
  • 1.6
  • 95.49
  • (% of float 03/29/19)
    1.41

Latest News

April 16, 2019
7:02 am ET
Globe Newswire
April 12, 2019
8:00 am ET
BusinessWire
April 02, 2019
8:00 am ET
BusinessWire
March 25, 2019
10:42 am ET
MarketWatch
March 19, 2019
6:49 am ET
MarketWatch
March 13, 2019
12:13 pm ET
MarketWatch
March 12, 2019
5:07 am ET
BusinessWire
March 06, 2019
9:32 am ET
BusinessWire
8:14 am ET
Globe Newswire
8:00 am ET
BusinessWire
February 25, 2019
7:59 am ET
Globe Newswire
February 21, 2019
4:01 pm ET
BusinessWire
February 14, 2019
9:04 am ET
BusinessWire
February 05, 2019
4:01 pm ET
BusinessWire
January 31, 2019
7:35 am ET
Globe Newswire
January 28, 2019
9:17 am ET
BusinessWire
January 23, 2019
4:30 pm ET
MarketWatch
4:05 pm ET
BusinessWire
January 22, 2019
4:01 pm ET
BusinessWire
January 11, 2019
4:43 pm ET
MarketWatch
January 02, 2019
7:17 am ET
MarketWatch
November 10, 2018
9:54 am ET
MarketWatch
November 08, 2018
5:34 am ET
MarketWatch
Go to all current & historical news

Earnings Calendar and Events Data provided by |Terms of Use| © 2019 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2019. All rights reserved.